Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12278
Title: Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Authors: Ong, Kevin T;Villemagne, Victor L;Bahar-Fuchs, Alex;Lamb, Fiona;Langdon, Narelle;Catafau, Ana M;Stephens, Andrew W;Seibyl, John;Dinkelborg, Ludger M;Reininger, Cornelia B;Putz, Barbara;Rohde, Beate;Masters, Colin L;Rowe, Christopher C
Affiliation: Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia Centre for Research on Aging, Health, and Wellbeing, The Australian National University, Acton, Australian Capital Territory, Australia.
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia.
Piramal Imaging GmbH, Berlin, Germany.
Molecular NeuroImaging, L.L.C., New Haven, Connecticut, USA.
Bayer Healthcare, Berlin, Germany.
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Issue Date: 26-Jun-2014
Citation: Journal of Neurology, Neurosurgery, and Psychiatry 2014; 86(4): 431-6
Abstract: We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time.45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMCI) was defined by a composite episodic memory (EM) Z-score of <-1.5.At baseline, 24 (53%) MCI were FBB+. Majority reads agreed with SUVR classification (κ 0.96). In 2 years, 18 (75%) FBB+ progressed to AD compared with 2 (9.5%) FBB-, yielding a predictive accuracy of 83% (95% CI 61% to 94%). Four FBB- developed non-AD dementia. Predictive accuracies of HV (58% (95% CI 42% to 73%)) and aMCI status (73% (95% CI 58% to 81%)) were lower. Combinations did not improve accuracy. By 4 years, 21 (87.5%) FBB+ had AD whereas 5 (24%) FBB- had non-AD dementia yielding a predictive accuracy of 94% (95% CI 74% to 99%). While the strong baseline association between FBB SUVR and EM declined over 2 years, the association between EM and HV became stronger. FBB SUVR increased 2.2%/year in FBB+ with no change in FBB-.(18)F-florbetaben Aβ imaging facilitates accurate detection of prodromal AD. As neurodegeneration progresses, and in contrast with the early stages of the disease, hippocampal atrophy and not Aβ, seems to drive memory decline.NCT01138111.
Internal ID Number: 24970906
URI: http://ahro.austin.org.au/austinjspui/handle/1/12278
DOI: 10.1136/jnnp-2014-308094
URL: http://www.ncbi.nlm.nih.gov/pubmed/24970906
Type: Journal Article
Subjects: ALZHEIMER'S DISEASE
AMYLOID
COGNITION
DEMENTIA
MRI
Aged
Alzheimer Disease.metabolism.radionuclide imaging
Amyloid beta-Peptides
Aniline Compounds.diagnostic use
Disease Progression
Female
Hippocampus.radionuclide imaging
Humans
Magnetic Resonance Imaging
Male
Memory Disorders.radionuclide imaging
Mild Cognitive Impairment.radionuclide imaging
Positron-Emission Tomography
Prospective Studies
Radiopharmaceuticals.diagnostic use
Stilbenes.diagnostic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.